Rexahn Pharmaceuticals (RNN) Offers Results from Phase II Trial of Serdaxin for Major Depressive Disorder

Rexahn Pharmaceuticals, Inc. (NYSE: RNN) today announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder. The randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 mg and 5 mg, to placebo over an 8-week treatment period. Results from the study did not demonstrate Serdaxin’s efficacy compared to placebo measured by the Montgomery-Asberg Depression Rating Scale (MADRS). All groups showed an approximate -14 point improvement in the protocol defined primary endpoint of MADRS. All groups had a substantial number of patients who demonstrated a meaningful clinical improvement from baseline. The study showed Serdaxin to be safe and well tolerated.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tenax shares Phase 3 LEVEL trial data at ESC Congress 2026
• FDA clears Adicet Bio IND application for prostate cancer therapy
• CRISPR Therapeutics reports one-year CTX310 lipid-lowering data